https://pub-bb88b7fd812d4deba11751c5338bb0aa.r2.dev/oncy_14.01.25.mp3https://markets-headlines.com/wp-content/uploads/2026/01/Precision-Killers-Why-Big-Pharma-is-Betting-Billions-to-Beat-a-170B-Patent-Cliff.mp4 Issued on behalf...
Read MoreEquity Insider News Commentary Issued on behalf of RUA GOLD Inc. VANCOUVER – Equity Insider News Commentary – Gold’s surge to record-breaking levels above $3,599 per ounce in September 2025[1] has catalyzed the most...
Read MoreEquity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Equity Insider News Commentary – Cancer innovation is reaching new heights as the FDA approved breakthrough therapies for aggressive...
Read MoreEquity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Equity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it...
Read MoreEquity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Equity Insider News Commentary – The average age of cancer patients is getting younger, as experts are urgently examining the rise of...
Read MoreUSA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research...
Read MoreEquity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Equity Insider News Commentary – As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures...
Read MoreKOL webinar to take place on July 22, 2025, at 1:00 p.m. ET SAN DIEGO, CA and CALGARY, AB, July 10, 2025 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for...
Read MoreEquity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive...
Read MoreEquity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it’s looking more and more like the solution...
Read MoreEquity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Equity Insider News Commentary – The 2025 ASCO Annual Meeting has wrapped, leaving behind a wave of cautious optimism across the oncology...
Read MoreEquity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is...
Read More